Corticosteroids in essential hypertension: Multiple candidate loci and phenotypic variation

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 5, 1996, Pages 369-374

  Connell, J M C ^a   Kenyon, C J ^a   Ingrain, M ^a   Holloway, C ^a   Jamieson, A ^a   Panarelli, M ^a   Inglis, G ^a   Fraser, R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Corticosteroid; Genotype; Hydroxylase; Hypertension; Phenotype; Receptor

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; BUDESONIDE; CORTICOSTEROID; CORTISONE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ESSENTIAL HYPERTENSION; HUMAN; NONHUMAN; RAT; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0029893576     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb02743.x     Document Type: Review

References (46)

1. Fraser R, Connell JMC. Corticosteroids and hypertension. J. Hypertens. 1991; 9: 97-107.
2. Greminger P, Tenschert W, Vetter W. Hypertension in Cushing's syndrome. In: Mantero F, Biglieri EG (eds). Endocrinology of Hypertension. London, Academic Press. 1982; 103-10.
3. Weber KT, Suny TJ, Agi SC, Cleutjens JPM. Collagen network of the myocardium: Function, structural remodelling and regulating mechanisms. J. Mol. Cell. Cardiol. 1994; 26: 279-92.
4. Fraser R, Davies DL, Connell JMC. Hormones and hypertension. Clin. Endocrinol. 1989; 31: 701-46.
5. Beretta-Piccoli C, Davies DL, Brown JJ et al. The relation of arterial pressure with plasma and body electrolytes is similar in Conn's syndrome and essential hypertension. Clin. Sci. 1982; 63: S89-92.
6. Morris AD, Petrie JP, Connell JMC. Insulin and hypertension. J. Hypertens. 1994; 12: 633-42.
7. Whitworth JA, Gordon D, McLachlan T, Scoggins BA, Moulds RWF. Dexamethasone suppression in essential hypertension: Effects on cortisol and blood pressure. Clin. Exp. Hypenens. 1989; A11: 323-3.
8. Williams GR, Franklyn JA. Physiology of the steroid-thyroid hormone nuclear receptor superfamily. Bailliere's Clin. Endocrin. Metab. 1994; 8: 241-66.
9. Evans RM. The steroid and thyroid hormone receptor superfamily. Science, 1988; 240: 889-95.
10. Panarelli M, Fraser R. The glucocorticoid receptor and hypertension. Endocrinol. Res. 1994; 20: 101-16.
11. Vingerhoeds ACM, Thijssen JHH, Schwarts F. Spontaneous hypercorticolism without Cushing's syndrome. J. Clin. Endocrinol. Metab. 1976; 43: 1128-33.
12. Lipsett MB, Tomita M, Brandon DD. Cortisol resistance in man. Adv. Exp. Med. Biol. 1986; 196: 97-109.
13. Arai K, Chrousos GP. Glucocorticoid resistance. Clin. Endocrinol. Metab. 1994; 8: 317-31.
14. Watt GCM, Harrap SB, Foy CJW et al. Abnormalities of glucocorticoid metabolism and the renin- angiotensin system: A four corners approach to the identification of genetic determinants of blood pressure. J. Hypertens. 1992; 10: 473-82.
15. Weaver JU, Hitman GA, Kopelman PG. An association between Bcl 1 restriction fragment length polymorphism of the glucocorticoid receptor locus and hyperinsulinaemia in obese women. J. Mol. Endocrinol. 1992; 9: 295-300.
16. Panarelli M, Holloway CD, Barr ABP, Fraser R, Kenyon CJ. Differences in temperature-sensitive binding of glucocorticoids in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Steroids 1995; 60: 73-5.
17. Funder JW, Pearce PT, Smith R, Smith AT. Mineralocorticoid action: Target tissue specificity is enzyme, not receptor mediated. Science 1987; 242: 583-5.
18. Stewart PM, Corrie JET, Shackleton CHL, Edwards CRW. Syndrome of apparent mineralocorticoid excess. A defect in cortisolcortisone shuttle. J. Clin. Invest. 1988; 82: 340-9.
19. Stewart PM, Valentino R, Wallace AM, Burt D, Shackleton CHL, Edwards CRW. Mineralocorticoid activity of liquorice: 11β-Hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; ii: 821-4.
20. Whitworth JA, Williamson PM, Brown MA, Edwards CRW. Haemodynamic and metabolic effects of carbenoxolone in normal subjects and patients with renal impairment. Clin. Exp. Hypertens. 1994; 116: 431-50.
21. Walker BR, Stewart PM, Padfield PL, Edwards CRW. Increased vascular sensitivity to glucocorticoids in essential hypertension: 11β-Hydroxysteroid dehydrogenase deficiency revisited. J. Hypertens. 1991; 9: 1082-3.
22. Soro A, Ingram M, Tonolo G, Glorioso N, Fraser R. Evidence of co-existing changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in subjects with untreated hypertension. Hypertension 1995; 25: 67-70.
23. Stewart PM, Murray BA, Mason J. Human kidney 11β hydroxysteroid is a high affinity NAD-dependent enzyme and differs from the cloned type I isoform. J. Clin. Endocrinol. 1994; 79: 480-4.
24. Albiston AL, Obeyeseuere V, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell. Endocrinol. 1994; 105: R11-17.
25. Jamieson A, Fraser R. Developments of the molecular biology of corticosteroid synthesis and action: Implications for an understanding of essential hypertension. J. Hypertens. 1994; 12: 503-9.
26. Mornet Z, Dupont J, Viteck A, White PC. Characterisation of two genes encoding human steroid 11β-hydroxylase (P45011β). J. Biol. Chem. 1989; 264: 20961-7.
27. Kawamoto T, Mitsuuchi Y, Ohnishi T. Cloning and expression of cDNA for human cytochrome P-450 ALDO as related to primary aldosteronism. Biochem. Biophys. Res. Commun. 1990; 173: 309-16.
28. Helmberg A. Twin genes and endocrine disease: CYP21 and CYP11B genes. Acta Endocrinol. 1993; 129: 97-108.
29. Inglis G, Kenyon CJ, Szpirer C, Klinga K, Sutcliffe RG, Connell JMC. Microsatellite polymorphism analysis allows the individual assignment of the rat 11β-hydroxylase gene (CYP11B1) and the rat aldosterone synthase gene (CYP11B2) to rat chromosome 7 using rat/mouse somatic cell hybrids and identifies differences between and within various rat strains. J. Mol. Endocrinol. 1995; 14: 303-11.
30. Fraser R. Inborn errors of corticosteroid biosynthesis and metabolism: Their effects on electrolyte metabolism. In: Robertson JIS (ed.). Handbook of Hypertension. Amsterdam, Elsevier. 1992; 420-60.
31. Rapp JP. Dahl salt-sensitive and salt-resistant rats. Hypertension 1982; 4: 753-63.
32. Rapp JP, Dahl LK. Mendalian inheritance of 18 and 11-beta steroid hydroxylase activities in the adrenals of rats genetically susceptible or resistant to hypertension. Endocrinology 1972; 90: 1435-46.
33. Cicila GT, Rapp JR, Wang JM, St Lezin E, Ng SC, Kurtz TW. Linkage of 11β-hydroxylase mutations with altered steroid biosynthesis and blood pressure in Dahl rat. Nature Genetics 1993; 3: 346-53.
34. Fraser R, Ancil AK, Brown WB et al. Hypertension in Milan rat. Evidence of abnormalities in corticosteroid secretion rate pattern leading to volume-dependent hypertension. Hypertension 1994; 24: 512-15.
35. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can. Med. Assoc. J. 1966; 95: 1109-19.
36. New PI, Peterson RE, Saenger P, Levine LS. Evidence of an unidentified ACTH-induced steroid hormone causing hypertension. J. Clin. Endocrin. Metab. 1976; 43: 1289-93.
37. Connell JMC, Kenyon CJ, Corrie JET, Fraser R, Watt R, Lever AF. Dexamethasone-suppressible hyperaldosteronism. Adrenal transition cell hyperplasia? Hypertension 1986; 8: 669-76.
38. Stockigt JR, Scoggins BA. Long term evolution of glucocorticoid suppressible hyperaldosteronism. J. Clin. Endocrinol. Metab. 1987; 98: 87-9.
39. Ulick S, Chu MD. Hypersecretion of a new corticosteroid, 18-hydroxycortisol, in two types of adrenocorticoid hyperplasia. Clin. Exp. Hypertens. 1982; 4: 1771-7.
40. Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262-5.
41. Lifton RP, Dluhy RG, Powers M et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nature Genetics 1992; 2: 66-74.
42. Pascoe L, Curnow KM, Slutsker L et al. Glucocorticoid suppressible hyperaldosteronism results from hybrid genes created by unequal crossover between CYP11B1 and CYP11B2. Proc. Natl Acad. Sci. USA 1992; 89: 8327-31.
43. Jamieson A, Inglis GC, Campbell M, Fraser R, Connell JMC. Rapid diagnosis of glucocorticoid suppressible hyperaldosteronism. Arch. Dis. Child. 1994; 71: 40-3.
44. Gordon RD, Zlesak MD, Tunny TJ, Stowasser M, Kremm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin. Exp. Pharmacol. Physiol. 1993; 20: 296-8.
45. Jamieson A, Slutsker L, Inglis GC, Fraser R, White PC, Connell JMC. Glucocorticoid-suppressible hyperaldosteronism: Effects of crossover site and parental origin of a chimaeric gene on phenotypic expression. Clin. Sci. 1995; 88: 563-70.
46. de Simone G, Tommaselli AP, Rossi R, Valentino R, Lauria R, Scopacasa F. Partial deficiency of adrenal 11-hydroxylase. A possible cause of primary hypertension. Hypertension 1985; 7: 204-10.